Overview

• U.S. biotech firm's Q1 net loss widened yr/yr as R&D and G&A expenses increased

• Company raised $144 mln in February public offering to support pipeline advancement

• Cash and equivalents rose to $225.6 mln, expected to fund operations through at least 2028

Outlook

• Zura expects topline data from HS Phase 2 study in Q4 2026

• Company expects topline data from SSc Phase 2 study in H1 2027

• Zura says cash position expected to fund operations through at least end of 2028

Result Drivers

• R&D SPENDING - Higher R&D expenses driven by advancement of Phase 2 tibulizumab clinical programs

• G&A COSTS - Increased G&A expenses due to higher compensation and professional fees to support growth and clinical programs

Company press release: ID:nBw2rJZTa

Key Details

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.